Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemarituzumab in advanced gastric or gastroesophageal junction cancer
NCT05052801Phase 3Completed
- Sponsor
- Amgen
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 37
01
Overview
A Phase 3 trial of bemarituzumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Amgen. Started Mar 2022; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05052801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052801.